The company has developed a minimally invasive implant that can be easily removed from the brain

Of all the emerging brain health startups, some of the most exciting are those developing brain-computer interfaces (BCIs), which allow people to control machines using their thoughts.

This is still an emerging space, with the best-known of these companies probably being Elon Musk’s Neuralink, but they have the potential to have a major impact on the lives of people living with neurological conditions such as the disease. Parkinson’s, which affects almost 100 million people. in the United States only. For example, BCIs can help people with paralysis regain control of their limbs, and this week it was reported that a team of Stanford scientists tested a new BCI that can decode speech down to a record 62 words per minute.

Precision Neuroscience Corporation, a BCI company developing implants designed to be high-resolution, minimally invasive and reversible, announced on Wednesday that it raised $41 million in Series B funding, bringing its total capital to $53 million.

Precision’s implant, called the Layer 7 Cortical Interface, is described as a strip of thin, flexible film material, which the company compares to a piece of duct tape, but “of a thickness that matches 1/5th that of a human hair”. .”

The implant is configured to conform to the surface of the brain without damaging tissue, allowing for easy removal. Each network of microelectrodes is composed of 1,024 electrodes, which gives it a density 600 times greater than standard cortical networks.

“Our electrode arrays will be implanted using a novel, minimally invasive cranial micro-slit technique. Unlike other approaches, Precision’s surgery is designed to be fully reversible. The arrays are configured to conform to the surface of the brain, maximizing bandwidth without damaging brain tissue,” the company says on its website.

Although minimally invasive, the company says the implant can still process large amounts of data.

The new funding round was led by Forepont Capital Partners, with Mubadala Capital, Draper Associates, Alumni Ventures and re.Mind Capital also participating, along with existing investors Steadview Capital and B Capital Group. Precision will use the capital to bolster its team, while further developing the product and preparing for FDA regulatory review, which it expects to undergo in the coming months.

“We envision a world where devastating neurological conditions – stroke, traumatic brain injury, dementia – are finally treatable,” said Michael Mager, CEO of Precision Neuroscience, in a statement.

“To reach this world, brain-computer interface technology must advance out of the lab and into the clinic. Precision is thrilled to take on this challenge.

(Image source:

Source link

Leave A Reply